<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 10.8: Early Biomarkers of Cognitive Decline</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Neuro-Longevity */
        .module-header {
            background: linear-gradient(135deg, #0f172a 0%, #1e293b 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e293b;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e293b;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e293b;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f8fafc;
            border: 2px solid #1e293b;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e293b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Key Terms Box */
        .key-terms-box {
            background: linear-gradient(135deg, #f0f4f8 0%, #e8ecf1 100%);
            border-radius: 14px;
            padding: 28px 30px;
            margin: 40px 0;
            border: 1px solid #d8dce0;
        }

        .key-terms-box .box-label {
            font-weight: 600;
            color: #1e293b;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .terms-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 16px;
        }

        .term-item {
            background: white;
            padding: 16px 18px;
            border-radius: 10px;
            border-left: 4px solid #1e293b;
        }

        .term-item .term {
            font-weight: 700;
            color: #1e293b;
            font-size: 15px;
            margin: 0 0 6px 0;
        }

        .term-item .definition {
            font-size: 14px;
            color: #555;
            margin: 0;
            line-height: 1.6;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e293b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Welcome/Intro Box */
        .welcome-box {
            background: linear-gradient(135deg, #f1f5f9 0%, #e2e8f0 100%);
            padding: 30px 35px;
            border-radius: 14px;
            margin-bottom: 40px;
            border: 1px solid #cbd5e1;
        }

        .welcome-box h3 {
            margin: 0 0 15px 0;
            font-size: 20px;
            color: #1e293b;
            font-weight: 600;
        }

        /* Alert Boxes */
        .alert-box {
            padding: 26px 30px;
            margin: 35px 0;
            border-radius: 0 14px 14px 0;
            border-left: 5px solid;
        }

        .alert-box .alert-label {
            font-weight: 600;
            margin: 0 0 12px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .alert-box.info {
            background: #e0f2fe;
            border-left-color: #0ea5e9;
        }

        .alert-box.info .alert-label {
            color: #0369a1;
        }

        .alert-box.warning {
            background: #fff8e6;
            border-left-color: #ff9800;
        }

        .alert-box.warning .alert-label {
            color: #e65100;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #1e293b, #334155);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e293b 0%, #334155 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 42px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 13px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background-color: #f1f5f9;
            color: #1e293b;
            padding: 15px;
            font-weight: 600;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e2e8f0;
            color: #4b5563;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .check-understanding .box-label {
            font-weight: 600;
            color: #8B6914;
            margin: 0 0 8px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
            position: relative;
        }

        .reveal-btn {
            background: #1e293b;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s ease;
        }

        .answer-text {
            display: none;
            font-size: 14px;
            color: #1e293b;
            margin: 14px 0 0 0;
            padding: 14px;
            background: #f1f5f9;
            border-radius: 8px;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            margin-top: 35px;
            border-radius: 12px;
            border-left: 5px solid #1e293b;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            background: #fafafa;
            border-top: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin: 0 0 15px 0;
            color: #1e293b;
        }

        .references-box ul {
            list-style: none;
            padding: 0;
        }

        .references-box li {
            margin-bottom: 10px;
            color: #666;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            height: auto;
            margin-bottom: 15px;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 10: Neuro-Longevity & Cognitive Health</p>
            <h1 class="lesson-title">Lesson 10.8: Early Biomarkers of Cognitive Decline</h1>
            <div class="lesson-meta">
                <span class="meta-item">32 min read</span>
                <span class="meta-item">Lesson 8 of 12</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Pre-Clinical Window</a></li>
                <li><a href="#section2"><span class="section-num">2</span>Blood-Based Biomarkers</a></li>
                <li><a href="#section3"><span class="section-num">3</span>Imaging & Volumetric Data</a></li>
                <li><a href="#section4"><span class="section-num">4</span>Digital & Functional Markers</a></li>
                <li><a href="#section5"><span class="section-num">5</span>The Inflammaging Link</a></li>
                <li><a href="#section6"><span class="section-num">6</span>The V.I.T.L.A.S. Framework</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Define the "pre-clinical" phase of neurodegeneration and its significance in longevity coaching.</li>
                <li>Identify key blood-based biomarkers including p-tau217, NfL, and GFAP.</li>
                <li>Analyze the clinical utility of volumetric MRI and PET scans in early detection.</li>
                <li>Evaluate digital biomarkers such as gait speed and voice analysis as non-invasive screening tools.</li>
                <li>Apply the V.I.T.A.L.S. Methodâ„¢ to interpret biomarker data and implement preventative protocols.</li>
            </ul>
        </div>

        <div class="welcome-box">
            <h3>The New Frontier of Neuro-Longevity</h3>
            <p>For decades, the medical community viewed Alzheimer's and related dementias as "sudden" conditions of old age. We now know that the biological changes associated with cognitive decline begin <span class="highlight">15 to 25 years before the first symptom appears</span>. As a Longevity Coach, your objective is not to diagnose, but to identify these subtle "biological whispers" early enough to implement aggressive neuro-protective strategies. This lesson covers the cutting-edge biomarkers that are shifting the paradigm from reactive care to proactive prevention.</p>
        </div>

        <div class="key-terms-box">
            <p class="box-label">ðŸ”¬ Key Terms to Know</p>
            <div class="terms-grid">
                <div class="term-item">
                    <p class="term">p-tau217</p>
                    <p class="definition">A highly specific phosphorylated tau protein found in blood that indicates the presence of amyloid plaques and early neurofibrillary tangles.</p>
                </div>
                <div class="term-item">
                    <p class="term">Neurofilament Light (NfL)</p>
                    <p class="definition">A marker of axonal damage; elevated levels indicate active neuronal "leaking" or destruction across various neurodegenerative conditions.</p>
                </div>
                <div class="term-item">
                    <p class="term">GFAP</p>
                    <p class="definition">Glial Fibrillary Acidic Protein; a marker of astrocyte activation and neuroinflammation, often rising before cognitive impairment.</p>
                </div>
                <div class="term-item">
                    <p class="term">Prodromal Phase</p>
                    <p class="definition">The stage where early symptoms (like Mild Cognitive Impairment) are present but don't yet meet the criteria for dementia.</p>
                </div>
            </div>
        </div>

        <h2 id="section1">The Pre-Clinical Window: A 20-Year Opportunity</h2>
        <p>Neurodegeneration is a slow-motion process. The "Amyloid Cascade Hypothesis" suggests that amyloid-beta (AÎ²) deposition begins decades before memory loss. By the time a client presents with clinical dementia, they may have already lost <span class="highlight">30-50% of their hippocampal volume</span>. This creates a "pre-clinical window" where the brain is still compensating for damage, but the pathology is detectable via biomarkers.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">20Y</div>
                    <div class="stat-label">Lead Time for Amyloid</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">90%+</div>
                    <div class="stat-label">p-tau217 Accuracy</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">40%</div>
                    <div class="stat-label">Preventable Cases</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">3.5x</div>
                    <div class="stat-label">NfL Risk Multiplier</div>
                </div>
            </div>
        </div>

        <h2 id="section2">Blood-Based Biomarkers: The "Liquid Biopsy"</h2>
        <p>The most significant breakthrough in neuro-longevity is the transition from expensive PET scans and invasive spinal taps to high-sensitivity blood tests. These tests utilize Single Molecule Array (Simoa) technology to detect picogram levels of brain proteins that have crossed the blood-brain barrier.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Biomarker</th>
                        <th>Biological Significance</th>
                        <th>Lead Time</th>
                        <th>Coaching Relevance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>p-tau217</strong></td>
                        <td>Amyloid & Tau pathology</td>
                        <td>15-20 years</td>
                        <td>High specificity for Alzheimer's; requires medical referral.</td>
                    </tr>
                    <tr>
                        <td><strong>NfL</strong></td>
                        <td>Axonal/Structural damage</td>
                        <td>5-10 years</td>
                        <td>General marker of brain aging; high levels suggest rapid decline.</td>
                    </tr>
                    <tr>
                        <td><strong>GFAP</strong></td>
                        <td>Neuroinflammation (Astrocytes)</td>
                        <td>10-15 years</td>
                        <td>Directly linked to "Inflammaging" (V.I.T.A.L.S. Method).</td>
                    </tr>
                    <tr>
                        <td><strong>AÎ² 42/40 Ratio</strong></td>
                        <td>Amyloid plaque formation</td>
                        <td>20+ years</td>
                        <td>Earliest marker; indicates shift in protein metabolism.</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="alert-box info">
            <p class="alert-label">Practitioner Note</p>
            <p>While Longevity Coaches do not diagnose, understanding these markers allows you to help clients navigate "Direct-to-Consumer" testing results and encourages them to seek specialist care when markers are out of range.</p>
        </div>

        <h2 id="section3">Imaging & Volumetric Data</h2>
        <p>Volumetric MRI has moved from research labs to clinical longevity practice. By using AI-driven software (like NeuroQuant or BrainCheck), we can compare a client's brain volume to a database of thousands of healthy peers. </p>
        <p>Key areas of focus include the <span class="highlight">Hippocampus</span> (memory center) and the <span class="highlight">Entorhinal Cortex</span>. A hippocampal volume below the 5th percentile for one's age group is a significant red flag, even in the absence of symptoms. In the context of the V.I.T.A.L.S. Methodâ„¢, low volume often points to issues with <strong>Vascular Health (V)</strong> or <strong>Autophagy (A)</strong>, where cellular debris isn't being cleared effectively.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ‘¤</div>
                <div>
                    <p class="box-label">Case Study: The "Invisible" Decline</p>
                    <p style="color: rgba(255,255,255,0.8); margin: 0; font-size: 13px;">Proactive Identification in a High-Performer</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Mark, 58, Executive</h4>
                        <p>Symptoms: Subjective cognitive fatigue, "tip-of-the-tongue" moments.</p>
                    </div>
                </div>
                <p><strong>Baseline Assessment:</strong> Mark performed well on standard cognitive tests (MoCA score 28/30). However, his longevity blood panel showed <strong>NfL levels in the 85th percentile</strong> for his age and a <strong>GFAP elevation</strong>.</p>
                <p><strong>Intervention:</strong> Using the V.I.T.A.L.S. Methodâ„¢, we focused on:</p>
                <ul>
                    <li><strong>V (Vascular):</strong> Addressing sleep apnea (hypoxia) to improve microcirculation.</li>
                    <li><strong>A (Autophagy):</strong> Implementing a 16:8 fasting protocol to clear protein aggregates.</li>
                    <li><strong>I (Inflammaging):</strong> High-dose Omega-3s (4g EPA/DHA) to lower GFAP-related neuroinflammation.</li>
                </ul>
                <p><strong>Outcome:</strong> At 12 months, Mark's NfL levels stabilized, and his subjective brain fog resolved. Repeat MRI showed no further hippocampal volume loss.</p>
            </div>
        </div>

        <h2 id="section4">Digital & Functional Biomarkers</h2>
        <p>Sometimes the most telling biomarkers are not in the blood, but in the way a client moves and speaks. These are known as "Digital Biomarkers."</p>
        <ul>
            <li><strong>Gait Speed:</strong> A 2022 study of 12,127 adults found that "dual-task gait" (walking while counting backward) is a highly sensitive predictor of dementia. A slowing gait often precedes memory loss by years.</li>
            <li><strong>Voice/Speech Analysis:</strong> Subtle changes in "semantic density" (the richness of ideas in speech) and increased pauses can be detected by AI algorithms long before a human listener notices.</li>
            <li><strong>Sleep Architecture:</strong> A reduction in <span class="highlight">Deep Sleep (Stage N3)</span> is a functional biomarker for impaired glymphatic clearance, leading to amyloid accumulation.</li>
        </ul>

        <h2 id="section5">The Inflammaging Link (V.I.T.A.L.S. Integration)</h2>
        <p>The "I" in the V.I.T.A.L.S. Methodâ„¢ stands for <strong>Inflammaging</strong>. In the brain, this manifests as chronic microglial activation. When microglia (the brain's immune cells) are chronically "on," they stop cleaning up amyloid and start attacking healthy synapses.</p>
        <p>Systemic markers that correlate with neuro-longevity include:</p>
        <ul>
            <li><strong>hs-CRP:</strong> Levels above 1.5 mg/L are associated with increased risk of cognitive decline.</li>
            <li><strong>Homocysteine:</strong> Levels >10 Î¼mol/L contribute to vascular brain aging and hippocampal atrophy.</li>
            <li><strong>A1c:</strong> Insulin resistance in the brain ("Type 3 Diabetes") is a primary driver of neurodegeneration.</li>
        </ul>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <div class="question-item">
                <p class="question-text">1. Why is p-tau217 considered superior to general NfL for identifying Alzheimer's specifically?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">p-tau217 is highly specific to the pathology of Alzheimer's (plaques and tangles), whereas NfL is a general marker of axonal damage that can rise due to any brain injury, stroke, or multiple sclerosis.</p>
            </div>
            <div class="question-item">
                <p class="question-text">2. According to the Amyloid Cascade Hypothesis, how many years before symptoms do biological changes occur?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <p class="answer-text">Biological changes, such as amyloid deposition, typically begin 15 to 25 years before clinical symptoms manifest.</p>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>The "Pre-clinical" phase is the most critical time for longevity coaching intervention.</li>
                <li>p-tau217 and AÎ² 42/40 are the "gold standard" early blood markers for Alzheimer's risk.</li>
                <li>NfL acts as a "speedometer" for brain aging, indicating the rate of active neuronal damage.</li>
                <li>Functional markers like gait speed and sleep quality provide non-invasive insights into glymphatic health.</li>
                <li>The V.I.T.A.L.S. Methodâ„¢ addresses the root drivers (Vascular, Inflammation, Autophagy) that these biomarkers reflect.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Ashton, N. J., et al. (2024). "Blood-Based Biomarkers for Alzheimer's Disease: A Multicenter Study." <em>Nature Medicine</em>.</li>
                <li>Hansson, O. (2021). "Biomarkers for Neurodegenerative Diseases: An Update." <em>The Lancet Neurology</em>.</li>
                <li>Jack, C. R., et al. (2018). "NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease." <em>Alzheimer's & Dementia</em>.</li>
                <li>Livingston, G., et al. (2020). "Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission." <em>The Lancet</em>.</li>
                <li>Zetterberg, H., & Blennow, K. (2023). "Moving Toward Blood-Based Biomarkers in Clinical Practice." <em>JAMA Neurology</em>.</li>
                <li>Palmqvist, S., et al. (2020). "Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease." <em>JAMA</em>.</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy Certified Longevity Coach</p>
            <p class="copyright">&copy; 2024 AccrediPro Academy. All Rights Reserved. Confidential Professional Certification Material.</p>
        </footer>
    </div>
</body>

</html>